Using the Best Evidence to Select the Best Contraceptive Jody Steinauer, MD, MAS Dept. Ob/Gyn &...
Preview:
Citation preview
- Slide 1
- Using the Best Evidence to Select the Best Contraceptive Jody
Steinauer, MD, MAS Dept. Ob/Gyn & Reproductive Sciences
University of California, San Francisco
- Slide 2
- Disclosure Statement I have nothing to disclose.
- Slide 3
- Do you place intrauterine contraception in your clinical
practice? a.Yes b.No
- Slide 4
- How comfortable would you be offering a woman an IUD if she had
a history of Chlamydia and no current infection? a.Very comfortable
b.Somewhat comfortable c.Uncomfortable
- Slide 5
- Would you offer a 20 year-old woman with migraine the combined
oral contraceptive? a.Yes b.It depends c.No
- Slide 6
- Objectives Remember contraception in your clinical practice.
Find evidence about contraception for women with possible
contraindications. Encourage women to use longer acting methods.
Address recent controversies and myths. Review extremely recent
& important information.
- Slide 7
- Jane is a 27 year-old woman taking combined oral contraceptive
pills, who presents to your clinic for an annual examination. She
reports having missed two periods. Her urine pregnancy test is
positive.
- Slide 8
- 6.4 Million US Pregnancies Annually 52 % Intended 48 %
Unintended Jones PSRH 2008
- Slide 9
- 6.4 Million U.S. Pregnancies Annually 52 % Intended 25 %
Unintended Despite method use 23 % Unintended No method used
Henshaw Family Planning Perspectives, 1998
- Slide 10
- Why did Jane get pregnant? Jane ran out of pills last month.
She tried to schedule an appointment, but because she was overdue
for a pap smear the clinic staff couldnt call in refills. Today was
the first day she could get an appointment.
- Slide 11
- Provider Barriers to Contraception Clinical Visit BP check to
initiate estrogen-containing methods No pap smear or other
examination Refill methods without seeing patient Remember birth
control 48% using D or X rx counseled on contraception 1 Knowledge
about contraindications US guidelines Schwarz Ann Intern Med,
2007.
- Slide 12
- Case: Counseling Issues After Jane has completed her pregnancy
she returns to you for contraceptive counseling. Jane has had
migraine headaches since she was a teen. She has no aura and they
have not changed with the combined pill. Can she use the pill
again?
- Slide 13
- Can my patient use this method? 1Can use the methodNo
restrictions 2Can use the methodAdvantages generally outweigh
theoretical or proven risks. 3Should not use method unless no other
method is appropriate Theoretical or proven risks generally
outweigh advantages 4Should not use methodUnacceptable health risk
WHO Medical Eligibility Criteria (MEC) www.reproductiveaccess.org
www.who.int
- Slide 14
- Medical conditions Birth control methods MEC Category
- Slide 15
- US MEC: 2010 Current WHO MEC contains > 1800 recommendations
No need to adapt most recommendations Science is the same
Recommendations are used around the world CDC accepted majority of
WHO recommendations Adapted a few for the US context
- Slide 16
- U.S. Medical Eligibility Criteria for Contraceptive Use (USMEC)
United States Medical Eligibility Criteria for Contraceptive Use
http://www.cdc.gov/reproductivehealth/unintendedpregnancy/USMEC.htm
http://www.cdc.gov/reproductivehealth/unintendedpregnancy/USMEC.htm
- Slide 17
- US MEC: 2010 Existing WHO guidance Breastfeeding and CHC
Breastfeeding and progestin only methods Postpartum IUDs Ovarian
cancer and IUDs Fibroids and IUDs DVT/PE and hormonal contraception
Valvular heart disease and IUDs New medical conditions Rheumatoid
arthritis Endometrial hyperplasia Inflammatory bowel disease
Bariatric surgery Solid organ transplantation Peripartum
cardiomyopathy
- Slide 18
- Migraine and Combined Hormonal Contraception (CHC)
- Slide 19
- Migraine, COC*, and Stroke Synergistic effect of Migraine and
COC OR 8.7 (95% CI 5.0-15.0) 1 OR 13.9 (95% CI 5.5-35.1) 2 Etminan
BMJ, 2005. Tzourio BMJ, 1995. *COC= combined oral contraceptive
pills
- Slide 20
- WHO/US: Headaches and CHC* Non-migrainous 1 Migraine (i) w/o
focal neurologic symptoms Age < 352 Age > 353 (ii) w/ focal
neurologic symptoms4 (at any age) Focal symptoms = AURA = vision
changes, numbness, parasthesias Non-focal = Prodrome,
photo/phonophobia, N/V
- Slide 21
- WHO/US: Headaches and CHC* InitiateContinue Non-migrainous1 2
Migraine (i) w/o focal neurologic symptoms Age < 352 3 Age >
353 4 (ii) w/ focal neurologic symptoms4 4 (at any age) Focal
symptoms = AURA = vision changes, numbness, parasthesias Non-focal
= Prodrome, photo/phonophobia, N/V
- Slide 22
- Absolute Risk of Stroke No COCCOC Healthy 6 per 100,000 /yr12
per 100,000 /yr Migraine 12 per 100,000 /yr19 per 100,000 /yr
Migraine + aura 18 per 100,000 /yr30 per 100,000 /yr Stroke in
pregnancy: 34 per 100,000 / year Speroff & Darney Clinical
Guide for Contraception 2005
- Slide 23
- Case: Counseling Issues After reviewing the US and WHO MEC you
decide Jane could use the pill again. But is it the best method for
her?
- Slide 24
- How effective is the combined oral contraceptive for prevention
of pregnancy? Typical use Perfect use
- Slide 25
- Natural Family Planning Contraceptive Method Failure Rate
Perfect UseTypical Use No Method85% Periodic Abstinence Standard
Days Method *5%12% Ovulation Method3%22% Symptothermal2%13-20%
Two-Day Method 3%14% * Including Cycle Beads National Center Health
Statistics; Contraceptive Technology
- Slide 26
- Barrier Methods Contraceptive Method Failure Rate Perfect
UseTypical Use Withdrawal4 %18 % Condoms2 %17 % Cervical Cap
(parous/nullip)26%/9%32%/16% Sponge
(parous/nulliparous)20%/9%32%/16% Female Condoms5 %27 % Diaphragm6
%16 % National Center Health Statistics; Contraceptive
Technology
- Slide 27
- Hormonal Methods Contraceptive Method Failure Rate Perfect
UseTypical Use Combined Hormonal Pills 10 mm at day 7 of placebo
week! If delay in new pack may ovulate! Baerwald, Contraception,
2004.
- Slide 40
- Extended Cycle: Shortened hormone-free week 23, 24 or 26 days
hormones + 2-5 d placebo Decreased ovarian activity at end of
placebo Shorter withdrawal bleeds Similar breakthrough bleeding 3
FDA-approved products in US New quadriphasic pill 2 d E, 22 d E+P,
2d E Start on cycle d 1; backup x 9 d Spona Contraception, 1996
Bachman Contraception, 2004 Endrikat Contraception, 2001.
- Slide 41
- Extended Cycle: Fewer hormone-free weeks 12 wks hormone/1 wk
off Ethinyl estradiol and levonorgestrel 84 days LNG 150 g/EE 30 g;
7 days placebo Decreased breakthrough bleeding over time Anderson
Contraception, 2003
- Slide 42
- Tricycle Breakthrough Bleeding/Spotting Anderson FD, et al.,
Contraception, 2003.
- Slide 43
- Extended Cycle: Continuous Use Continuous for one year
Increased spotting in first six months Median 1.5 days spotting in
last trimester FDA-approved: ethinyl estradiol and levonorgestrel
90 mcg levonorgestrel + 20 mcg EE Miller Obstetrics and Gynecology,
2003. Kwiecen, Contraception, 2003. Foidart, Contraception,
2006.
- Slide 44
- Choosing a COC Estrogen dose Low dose = < 50 mcg Progestin
type 1 st -generation: norethindrone Second-generation:
levonorgestrel Third-generation: desogestrel Drospirenone:
spironolactone derivative VTE risk Increased risk with 3 rd
generation progestin OR= 1.7 (1.4-2.0) Increased risk with
drospirenone OR = 1.64 (1.27 to 2.10) Kemmeren BMJ 2001; Lidegaard
BMJ 2009
- Slide 45
- Choosing a COC Careful with very low-dose estrogen bleeding
Monophasic fine No drospirenone Increased risk VTE PMDD: fewer sxs
6 months equivalent at 2 yr Acne: Equivalent to other pills 30 or
35 mcg EE + 2nd generation progestin Shortened or erased placebo
week if possible Monophasic VanViet Cochrane 2006 LaGuardia
Contraception, 2003 Freeman Womens Health 2001 van Vloten Cutis
2002
- Slide 46
- Jane no longer wants to take a pill every day. She asks you
about other birth control methods which she doesnt have to think
about as often. What can you offer her? Weekly Monthly 3 months 3
years 5-10 years
- Slide 47
- Daily: Progestin-only Pills (POPs) 35 mcg norethindrone DAILY
No hormone free interval!! Primary mechanism = cervical mucus
thickening Requires very punctual dosing If > 3 hours late, need
back up x 48 hours
- Slide 48
- Weekly: Transdermal Contraception Patch Norelgestromin and EE
20mcg EE & 150mcg norelgestromin One patch each week for 3
weeks, then week off Better compliance than with pill (88% v. 78%)
Audet JAMA, 2001
- Slide 49
- Weekly: Patch Few side effects comparable to pills except: 20%
skin irritation 2% stopped method More breast discomfort in first 2
cycles (19%) than pills (6%) More spotting (20%) than pills in
first 2 cycles 3% detached recent RCT 46% experience at least one
detachment in one cycle Prescribe replacement patch Creinin Obstet
Gynecol 2008
- Slide 50
- Patch and VTE* 2 studies, 2 results No association: 1,2 59K
patch & 147K OC users Risk of non-fatal VTE: OR=0.9 (CI 0.51.6)
1 OR=1.1 (CI 0.62.1) 2 All were new users No chart review
Association: 3 99K patch & 257K OC users Risk of non-fatal VTE:
OR=2.4 (CI 1.1-5.5) 3 New users: OR=2.2 (0.8-6.1) Charts reviewed
1.Jick SS Contraception 2006; 2. Jick SS Contraception 2007 3. Cole
JA Obstet Gynecol 2007 Case control studies from insurance claims.
Patch vs. 35mcgEE/norgestimate Better study supports increased
risk.
- Slide 51
- EE Exposure with combined hormonal contraception van den
Heuvel, Contraception 2005 (*30 mcg EE COC) AUC (pg/ml): Patch =
37.7 + 5.6 COC = 22.7 + 2.8 Ring = 11.2 + 2.7
- Slide 52
- Patch & Body Weight 3,319 patch users, 22,160 cycles 15
failures overall 0.8% failure 7 of them wt>80Kg 5 of them wt
>90kg (90kg (198 lbs) Zieman M, Fertil & Steril, 2002
- Slide 53
- Monthly: Contraceptive Vaginal Ring Ethinyl estradiol and
etonogestrel 15 mcg EE & 120 mcg desogestrel One ring each
month: Ring in vagina x 3 wks Ring removed x 1 week Constant, low
hormone levels Miller Obstet and Gynecol, 2005.
- Slide 54
- Monthly: Ring Few side effects comparable to pills except
Spotting: only 5% (significantly less in first month) Discharge: 1%
stop method Discomfort: 2.5% stop method Expulsion: recent RCT: 20%
expelled at least once during 3-week period Dieben Obstet Gynecol,
2002 Creinin Obstet Gynecol, 2008
- Slide 55
- Monthly: Extended Cycle Ring RCT of 561 : 4wk, 8 wk, 12 wk,
continuous: All regimens well-tolerated Extended: bleeding days,
spotting days Potential for use on a monthly basis Serum levels for
35 days I instruct patients to remove ring the last 3-4 days of the
month if they want withdrawal bleed. Miller Obstet Gynecol,
2005
- Slide 56
- Every 3 months: Progestin Injection Medroxyprogesterone acetate
150 mg IM One injection every 12-13 weeks Very effective Typical
use failure = 3% Side effects: Delayed return to fertility (9-10
months) Irregular bleeding, amenorrhea (50% at 1 yr) Weight gain (5
lbs at 1 year, 16 lbs at 5 yrs) SQ low-dose (104 mg) version now
available
- Slide 57
- Progestin Injection & BMD BMD decreases by 1-2% per year
FDA: limit to 2 yrs. in young women WHO & ACOG do not agree
Bone loss reverses by 1 year after discontinuation. No indication
for DEXA Weigh risks against risk of pregnancy New evidence of
increased fractures (OR 1.4, CI1.2-1.6) Overall risk is VERY low
and returns to baseline 2yrs after d/c. Meier, J Clin Endocrin
Metab, 2010. Scholes Arch Pediatr Adolesc Med, 2005.; Scholes,
Epidemiology, 2002; ACOG 2008 Com Opin 415.
- Slide 58
- Progestin Injection: Delay Traditionally recommend caution
after > 14 weeks from last DMPA injection WHO recommends 4-week
grace period Repeat up to 16 weeks
- Slide 59
- Missed Hormonal Contraceptives: New Recommendations Guidelines
for CHC and DMPA For CHC: The hormone free interval (HFI) not >
7 days In the 1 st week Back-up should be used after >1 missed
dose until 7 days of use occur. Consider EC. In the 2 nd and 3 rd
week If < 3 days are missed, eliminate the next HFI If > 3
days are missed, back-up contraception and consideration of EC
should be added Soc Ob GYN of Canada, JOGC 2008; 219:1050-62
- Slide 60
- Every 3 years: Single-Rod Implant Etonogestrel 60mcg/day
Efficacy > 99% Very easy & well tolerated to insert 1 year
continuation: 75%-90% Reasons for discontinuation: Bleeding
(11-40%) Mood swings (10%) Weight gain (10%) Blumenthal Eur J
Contracept Reprod Health Care, 2008
- Slide 61
- Progestin Implant: Side Effects Bleeding: Irregularly irregular
(40%) Amenorrhea: 22% 7% frequent: > 5 B-S episodes in 90-day
period 18% prolonged: at least 1 B-S episode > 14 days 20% have
B-S for >50 days in first 90-day period Generally NOT heavy
Weight: minor changes (2.3%) Mean weight gain = 3.7 lbs at year 2
Blumenthal Eur J Contracept Reprod Health Care, 2008. Mansour Eur J
Contracept Reprod Health Care 2008.
- Slide 62
- Implant: Bleeding Treatment Estrogen reduces number of bleeding
days with 6-rod implant (and DMPA) 50 mcg Ethinyl Estradiol x 14-21
d Mifepristone reduces number of days Plus 20 mcg EE NSAIDS mixed
results Ibuprofen 800mg po TID x 5 d Mefenemic acid 500 mg po BID x
5 d Aspirin 80 mg po qd x 10 d I recommend 1) Ibuprofen 2) 30 mcg
COC or higher dose ERT
- Slide 63
- Every 5-10 Years: Intrauterine Devices (IUD, IUC, IUD, IUS)
Levonorgestrel Intrauterine System (LNG-IUS) Levonorgestrel 20
mcg/day 0.1% failure (1 yr) 1.1% (7 yr ) Copper T 380A IUD 0.8%
failure (1 yr) 1.2% failure (7 yr) Lockhat Fertil Steril, 2005
Comparable to BTL failure rate of 1.8% /10 yrs 10 years 5
years
- Slide 64
- Worldwide Use of IUD Population Reference Bureau, 2002. Asia %
Using IUD Europe Latin America & Caribbean AfricaOceania North
America
- Slide 65
- IUD Review Current IUDs do NOT cause PID!!! Transient increased
risk at time of insertion STI at time of insertion increases risk
GC/CT screening can follow CDC guidelines Okay to screen on
insertion day treat if + Beyond time of insertion Overall decreased
risk with LNG IUS No increased risk with Copper IUD Okay to treat
for PID with IUD in place Svensson L, et al. JAMA. 1984; Sivin I,
et al. Contraception. 1991. Farley T, et al. Lancet. 1992;
Hubacher, NEJM, 2003.
- Slide 66
- Rate of PID by Duration of Use Rate per 1000 Woman- Years 20
days 21 days - 8 years n= 20,000 women. Adapted from Farley T, et
al. Lancet. 1992;339:785-788. Baseline PID risk: 1-2 cases /TWY
Duration
- Slide 67
- IUDs in Nulliparous Women Use by nulliparous women is safe and
effective 1-4 LNG-IUS is appropriate for nulliparous women with
menorrhagia and/or dysmenorrhea IUD expulsion, bleeding, and pain
are slightly more likely among nulliparous women 2-5 Suhonen S.
Contraception 2004;69:507-512 Nelson AL. Obstet Gynecol Clin North
Am. 2000;27:723-740 Dardano KL, Burkman RT. Am J Obstet Gynecol.
1999;181:1-5 Li C. Contraception 2004;69:247-250 Treiman K, et al.
Population Reports. 1995
- Slide 68
- IUD & Vaginal Bleeding Study Group Mean Blood Loss (mL)
Control35 Paragard 50-80 Mirena5 After 12 mos: average 90% decrease
blood Increased spotting common in first 3-6 months 50% have
amenorrhea by 1 year Speroff & Darney Clinical Guide for
Contraception 2005
- Slide 69
- Is Jane a candidate for an IUD? Women of any reproductive age
seeking long-term, highly effective contraception
- Slide 70
- Postpartum Intrauterine Contraception
- Slide 71
- 2010 US MEC: Postpartum IUD Insertion Postpartum (BF or non-BF
women) including post- caesarean section LNG-IUDCu-IUD = 17 years
Can be effective up to 5 days after unprotected sex No exam or
pregnancy test required
- Slide 78
- Emergency Contraception Levonorgestrel 1.5 mg Single-dose
tablet Labeled for 72 hours from last intercourse Two tablet dose
new name Same as old Plan B Labeling: 1 tab Q12 hours; off label: 2
tablets at once Ulipristal Acetate (UPA): 30 mg Selective
progesterone receptor modulator Taken orally in single 30 mg dose
Approved in Europe(2009) for up to 5 days
- Slide 79
- Jane You counsel Jane about the other options available,
emphasizing those with high efficacy that require less
intervention. She ends up choosing a highly effective IUD which you
place that same day.
- Slide 80
- Summary Unintended pregnancy remains a common problem in the US
Many effective methods available Minimize barriers to contraception
Provider, systemic, and patient Encourage more effective methods
Use USMEC guidelines
- Slide 81
- Resources WHO and US Medical Eligibility Criteria for
Contraceptive Use www.who.int www.cdc.gov www.cdc.gov
www.reproductiveaccess.org A Pocket Guide to Managing Contraception
UCSF Family Planning Consult Service (415) 443-6318
- Slide 82
- Acknowledgments Thanks to all who have shared slides Carolyn
Sufrin Mike Policar Phil Darney Sarah Prager